Researchers looked at 189 patients with diabetic macular edema who were receiving ranibizumab treatment. The study focused on how different biological markers, such as CREG1 levels, might be linked to how well the treatment works to resolve swelling in the eye.
The study found that patients who did not respond well to the treatment often had lower levels of CREG1 and lower eGFR. These non-responders also showed higher HbA1c, NLR, and PLR levels, along with more retinal detachment. On the other hand, higher CREG1 levels were linked to a better response to the medication.
Because this was a retrospective study, it only shows an association between these markers and treatment success. It does not prove that these levels cause the treatment to fail or succeed. The findings are based on a single group of patients, so more research is needed to see if these results apply to everyone.
Patients should talk to their eye care specialists about their specific treatment progress and any markers that might be relevant to their care.